Select Publications

Bonomi PD et al. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 2007;13(15 Pt 2):s4606-12. Abstract

Bunn PA Jr, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: More treatment options; more things to consider. Conclusion. Oncologist 2008;13(Suppl 1):37-46. Abstract

Ciuleanu T et al. Maintenance pemetrexed plus best supportive care (BCS) versus placebo plus BSC: A phase III study. Proc ASCO 2008;Abstract 8011.

Riely GJ et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(3 Pt 1):839-44. Abstract

Scagliotti GV et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell
lung cancer. J Clin Oncol 2008;26(21):3543-51. Abstract

Scagliotti G et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) which may impact future treatment decisions. 12^th World Conference on Lung Cancer 2007;Abstract PRS-03.

Home

EDITOR
Neil Love, MD

INTERVIEWS

Thomas J Lynch, MD
- Select publications

F Anthony Greco, MD
- Select publications

Robert Pirker, MD
- Select publications

Lung Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office